ACADIA Pharmaceuticals Hits New 52-Week High of $29.64

ACADIA Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 29.64 on August 10, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly notable given its market capitalization of USD 3,538 million, classifying it as a small-cap stock. Over the past year, ACADIA Pharmaceuticals has demonstrated impressive growth, with a performance increase of 97.51%, significantly outpacing the S&P 500's 21.34% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 9.00, indicating a favorable valuation relative to its earnings. Additionally, ACADIA's return on equity is a robust 31.86%, reflecting effective management and profitability. Despite a debt-to-equity ratio of -0.66, which suggests a strong balance sheet, the company does not currently offer a dividend yield. The stock's previous 52-week low was recorded at USD 19.69, highlighting the substantial upward movement in its price. This performance positions ACADIA Pharmaceuticals as a noteworthy player in its industry.